IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Porunellor A. Mathew and Kent Boles
Serial No.:	10/021,741
Filed:	12/12/2001
For:	**IMMUNO-ACTIVATION OF CS1 RECEPTOR IN NATURAL KILLER CELLS TO INHIBIT TUMOR CELL GROWTH.**
Group No.:	1642
Examiner:	Canella, Karen A.

RESPONSE UNDER 37 C.F.R. 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1642

Mail Stop AF
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on February 2, 2004.

M. Alford
(Printed or typed name of person signing the certificate)

M. Alford
(Signature of the person signing the certificate)

AMENDMENT AFTER FINAL UNDER 37 C.F.R. § 1.116

Responsive to the Final Office Action dated December 2, 2004, having a shortened statutory period for responding expiring March 2, 2005, and the two-month period expiring on February 2, 2005, please amend the above-identified patent application as follows:

In the Claims:

PLEASE AMEND CLAIMS AS FOLLOWS:

1. (Withdrawn) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a proteinaceous molecule or biological equivalent, wherein the encoded proteinaceous molecule or biological equivalent has a predicted peptide sequence homologous to a subset of a CD2 family of receptors, a predicted length of about 335 amino acids; a predicted intracellular domain of about 85 amino acid residues; a predicted extracellular domain of about 225 amino acid residues; and a predicted single transmembrane domain of about 25 amino acid residues.

2. (Withdrawn) The isolated nucleic acid molecule of claim 1, wherein the nucleic acid sequence comprises nucleotides of SEQ ID NO 1.